ASH 2023 | CD16, CD57 and DNAM-1 positive NK cells predict MRD negativity in MM treated with D-VTD

Charlotte Korst, MD, PhD, VU University, Amsterdam, The Netherlands, presents the findings of an immunomonitoring analysis in patients with newly diagnosed multiple myeloma (NDMM) who were enrolled in the Cassiopeia trial (EudraCT: 2014-004781-15). Patients were randomized to receive daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTD) or VTD alone, followed by autologous stem cell transplantation (autoSCT). Those who achieved a partial response (PR) or better were randomized to daratumumab maintenance or observation. Bone marrow (BM) and peripheral blood (PB) samples were collected at baseline and during treatment, and flow cytometry was used to investigate natural killer (NK) immunophenotypic profiles. Of the patients treated with D-VTD, those with a high percentage of CD16, CD57, and DNAM-1 positive NK cells were more likely to achieve measurable residual disease (MRD)-negativity post-consolidation. During treatment, patients also exhibited NK phenotypic changes and decreased absolute NK cell counts. In those who did not receive daratumumab maintenance, these changes and absolute counts were restored following cessation of treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.